Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Line item | Sando Pharma | Med Parmasi Group | Pip Company | Grasse Pharma Georgia | Medimex |
|---|---|---|---|---|---|
| Total Revenue | 5,621 | 2,610 | 2,112 | 1,400 | — |
| Total COGS | -5,045 | -1,537 | -1,402 | -1,364 | — |
| Gross Profit | 576 | 1,073 | 710 | 36 | — |
| Gross Margin | 10.3% | 41.1% | 33.6% | 2.6% | — |
| Total Operating Expenses | -799 | -858 | -823 | 0 | — |
| EBITDA | -222 | 214 | -113 | 36 | — |
| EBITDA Margin | -4.0% | 8.2% | -5.3% | 2.6% | — |
| Total D&A | -15 | -54 | -3 | 0 | — |
| EBIT / Operating Income | -237 | 160 | -115 | 36 | — |
| Total Interest Expense | -21 | -13 | — | — | — |
| Total Other Income | 53 | -14 | 215 | -1,245 | — |
| Profit Before Tax | -204 | 133 | 100 | -1,209 | — |
| Total Income Tax | 0 | -20 | -61 | 0 | — |
| Net Profit / (Loss) | -204 | 113 | 11 | -1,209 | — |
| Net Margin | -3.6% | 4.3% | 0.5% | -86.4% | — |
Not every picked company reports every selected year — FY2021: no filing for Medimex. Those cells are left blank (no filing), not zero.
| Company | Sector | EBITDA margin · FY 2021 | Percentile | Sector n |
|---|---|---|---|---|
| Med Parmasi Group | Pharma | 8.2% | 35th pct | 116 |
| Grasse Pharma Georgia | Pharma | 2.6% | 18th pct | 116 |
| Sando Pharma | Pharma | -4.0% | 9th pct | 116 |
| Pip Company | Pharma | -5.3% | 8th pct | 116 |
| Medimex | Pharma | — | no FY data | 116 |
Percentile is within each company's own sector across the whole FY2021 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.